Stock Movers Nvidia Agrees to Groq Licensing Deal; India's Coforge Buys Encora; Biohaven Tumbles
4 snips
Dec 26, 2025 Nvidia is making waves with a new licensing deal with Groq, enhancing its dominance in AI technologies. Meanwhile, Coforge is shaking things up with its $2.35 billion acquisition of Encora, tapping into cutting-edge AI and digital engineering skills. In a disappointing turn, Biohaven's experimental depression drug fell short in trials, negatively impacting its stock. The podcast dives into the strategic shifts in India's tech landscape and the implications for the IT sector, promising insightful analysis on these pivotal market movements.
AI Snips
Chapters
Transcript
Episode notes
Nvidia Expands Inferencing Arsenal
- Nvidia licensed Groq's inference tech and hired key executives to boost its AI inferencing capabilities.
- The move signals Nvidia's push to integrate diverse inference approaches into its product lineup.
Coforge Makes Major Digital Engineering Bet
- Coforge is buying Encora in an all-stock $2.35 billion deal to add AI, data and product engineering skills.
- The acquisition reflects Indian IT firms shifting toward higher-value digital engineering amid slowing traditional outsourcing demand.
Biohaven Trial Misses Key Endpoint
- Biohaven's mid-stage study of BHV-7000 for major depressive disorder missed its primary endpoint.
- The miss sent the stock sharply lower despite some subgroup trends favoring the drug.